Skip to main content
Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model

Fig. 6

Characterization of TME patterns in the TIDE subtypes. A Differences of tumor purity and ESTIMATEScore among the TIDE subtypes. B Hypergeometric tests revealed an association between TME patterns and TIDE subtypes. Gray lines represent no significance. C Boxplots showing comparisons of stromal cells abundance among the three TIDE subtypes of TCGA-BLCA. Cell proportions are assessed by the SCDC algorithm. D H&E histological images of the three subtypes from the real-world BC samples. Scale bar, 100 μm. E, F Transcription levels of representative fibrosis marker FAP and immune infiltration marker CD45 (PTPRC) in the TCGA-BLCA (E) and LY Dataset (F) among the TIDE subtypes. G IF images of FAP and CD45 (PTPRC) in three TIDE subtypes from the real-world BC samples. Scale bar, 100 μm. H Analysis of mean fluorescence intensity (AU) of FAP and CD45 (PTPRC) in the TIDE subtypes. I–K Comparisons of the concentration of pro-inflammatory (IL-6, IL-8) (I), anti-inflammatory (IL-4, IL-10) (J), and regulatory cytokines (IFN-α, IL-12p70) (K) in the collected urine samples from BC patient measured by ELISA among the TIDE subtypes. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; ns, no significance

Back to article page